María Victoria
Mateos Manteca

Profesora Titular de Universidad

Foto de María Victoria

Foto de Champalimaud Foundation

Champalimaud Foundation

Lisboa, Portugal

Publications in collaboration with researchers from Champalimaud Foundation (5)

2025

Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial
The Lancet Oncology

2021

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE
Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 11, pp. 785-798
Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial
BMC Cancer, Vol. 21, Núm. 1

2020

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial
The Lancet, Vol. 395, Núm. 10218, pp. 132-141

2019

Chimeric antigen receptor T-cell therapy for multiple myeloma: A consensus statement from the European Myeloma Network
Haematologica, Vol. 104, Núm. 12, pp. 2358-2360